What is the recommended titration protocol for an adrenaline (epinephrine) infusion in a 50 kg patient to achieve a mean arterial pressure of ≥65 mmHg?

How to Titrate Adrenaline Infusion

For a 50 kg patient with shock requiring adrenaline to achieve MAP ≥65 mmHg, start with 0.05 mcg/kg/min (2.5 mcg/min), titrate every 10-15 minutes in increments of 0.05-0.2 mcg/kg/min up to a maximum of 2 mcg/kg/min (100 mcg/min), with continuous invasive blood pressure monitoring mandatory.

Initial Preparation and Setup

Dilution Protocol 1:

• Dilute 1 mg (10 mL of 0.1 mg/mL) in 1,000 mL of 5% dextrose to achieve 1 mcg/mL concentration
• Stable for 4 hours at room temperature or 24 hours refrigerated
• Do not use saline alone as the diluent

Vascular Access 1:

• Infuse into a large central vein whenever possible
• Avoid leg veins in elderly or those with vascular disease
• Avoid catheter tie-in techniques that may cause stasis

Titration Protocol for Septic Shock

Starting Dose 1

For a 50 kg patient:

• Initial rate: 0.05 mcg/kg/min = 2.5 mcg/min = 150 mL/hr (using 1 mcg/mL dilution)
• This is the FDA-approved starting dose for septic shock

Titration Schedule 1

Every 10-15 minutes, assess MAP and adjust:

• If MAP <65 mmHg: Increase by 0.05-0.2 mcg/kg/min (2.5-10 mcg/min for 50 kg patient)
• Continue titrating until MAP ≥65 mmHg achieved
• Maximum dose: 2 mcg/kg/min = 100 mcg/min = 6,000 mL/hr

Practical Dosing Increments for 50 kg Patient

• Start: 2.5 mcg/min (150 mL/hr)
• Step 1: 5 mcg/min (300 mL/hr)
• Step 2: 7.5 mcg/min (450 mL/hr)
• Step 3: 10 mcg/min (600 mL/hr)
• Continue in 2.5-5 mcg/min increments as needed

Critical Monitoring Requirements

Mandatory Continuous Monitoring 2:

• Invasive arterial blood pressure monitoring - essential to prevent overshoot and detect minute-to-minute changes
• Continuous ECG monitoring for arrhythmias
• If invasive monitoring unavailable but patient profoundly hypotensive after multiple epinephrine boluses, proceed with every-minute BP cuff measurements

Hemodynamic Response Timeline 3, 4:

• Expect MAP to begin rising within 5 minutes of initiation or dose increase
• Peak effect typically within 15-20 minutes
• If no response after 15 minutes at current dose, increase dose
• Recent evidence shows higher initial doses (0.1 mcg/kg/min) produce faster and larger MAP increases than lower doses 4

Weaning Protocol

After Hemodynamic Stabilization 1:

• Decrease incrementally every 30 minutes over 12-24 hours
• Reduce by 0.05-0.1 mcg/kg/min per step
• Monitor for recurrent hypotension with each reduction

Special Circumstances and Caveats

When Standard Dosing May Be Insufficient 4

• If baseline MAP <50 mmHg, starting dose of 0.05 mcg/kg/min may fail to achieve target within 60 minutes
• Consider starting at 0.1 mcg/kg/min (5 mcg/min for 50 kg) in severe hypotension
• Failure to achieve MAP ≥65 mmHg within 60 minutes associated with increased mortality

Anaphylaxis Context 2

The titration differs substantially:

• Only use IV infusion after multiple IM doses have failed (0.3-0.5 mg IM every 5-20 min)
• Alternative concentration: 1 mg in 250 mL D5W = 4 mcg/mL
• Start at 1-4 mcg/min (NOT per kg), titrate to maximum 10 mcg/min
• For 50 kg patient: 0.02-0.08 mcg/kg/min starting range
• High risk of lethal arrhythmias - use only when absolutely necessary

Cardiac Arrest Dosing 2

Completely different protocol:

• Initial: 0.01 mg/kg (1 mL/kg of 1:10,000) IV every 3-5 minutes
• High-dose: 0.1 mg/kg (1 mL/kg of 1:1000) for refractory arrest
• Infusion: 4-10 mg/min after ROSC if needed

Common Pitfalls to Avoid

1. Using saline as sole diluent - FDA label specifically warns against this 1
2. Inadequate monitoring - Never run adrenaline without continuous BP monitoring in shock states
3. Peripheral IV extravasation - Causes tissue necrosis; use phentolamine 0.1-0.2 mg/kg (max 10 mg) in 10 mL saline injected locally if occurs 5
4. Fixed MAP target of 65 mmHg for all patients - Consider higher targets (70-80 mmHg) in chronic hypertensives who show clinical improvement 6
5. Too-slow titration - In severe hypotension (MAP <50 mmHg), aggressive early titration may be needed to achieve target within 60 minutes 4

Adverse Effects Requiring Dose Reduction

Monitor for 1:

• Severe hypertension (MAP >90-100 mmHg)
• Cardiac arrhythmias (especially ventricular)
• Myocardial ischemia (chest pain, ST changes)
• Oliguria/renal impairment (excessive vasoconstriction)
• Pulmonary edema

The evidence strongly supports starting at the lower end of the dosing range with careful titration, but recent data 4 suggests that in profound shock, more aggressive initial dosing may be necessary to achieve timely hemodynamic goals and improve outcomes.